他汀不耐受患病率的荟萃分析
结果显示总体SI患病率为9.1%(95%CI 8.0-10%),按国际定义诊断时患病率较低,提示完全性SI的患病率常被高估,需仔细评估有相关症状的患者。
要点
- 总体他汀不耐受患病率为9.1%(95%CI 8.0-10%)
- 随机对照试验中患病率(4.9%)显著低于队列研究(17%)
- 年龄、女性、亚洲及黑人种族、肥胖、糖尿病、甲状腺功能减退等与SI风险升高相关
主要发现
- 总体他汀不耐受患病率为9.1%(95%CI 8.0-10%)。
- 按NLA、ILEP和EAS标准定义时患病率相似,分别为7.0%(95%CI 6.0-8.0%)、6.7%(95%CI 5.0-8.0%)、5.9%(95%CI 4.0-7.0%)。
- 随机对照试验中患病率为4.9%(95%CI 4.0-6.0%),显著低于队列研究的17%(95%CI 14-19%)。
- 同时纳入一级和二级预防患者的研究中患病率为18%(95%CI 14-21%),高于单独分析一级预防(8.2%,95%CI 6.0-10%)或二级预防(9.1%,95%CI 6.0-11%)的研究。
- 他汀脂溶性不影响SI患病率(4.0% vs 5.0%)。
关键数值与推荐
- 年龄(OR 1.33,P=0.04)、女性(OR 1.47,P=0.007)、亚洲和黑人种族(两者P<0.05)、肥胖(OR 1.30,P=0.02)、糖尿病(OR 1.26,P=0.02)、甲状腺功能减退(OR 1.37,P=0.01)、慢性肝病和肾功能衰竭(两者P<0.05)与SI显著相关。
- 抗心律失常药、钙通道阻滞剂、饮酒及他汀剂量增加也与SI风险升高相关。
临床怎么用
- 临床遇到疑似他汀不耐受患者时应仔细评估,避免将完全性SI过度诊断,依据国际定义(NLA、ILEP、EAS)进行判断。
- 对于高龄、女性、亚洲或黑人种族、肥胖、糖尿病、甲状腺功能减退、慢性肝肾功能衰竭等高风险患者,应加强监测与个体化管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Statin intolerance (SI) represents a significant public health problem for which precise estimates of prevalence are needed. Statin intolerance remains an important clinical challenge, and it is associated with an increased risk of cardiovascular events. This meta-analysis estimates the overall prevalence of SI, the prevalence according to different diagnostic criteria and in different disease settings, and identifies possible risk factors/conditions that might increase the risk of SI. METHODS AND RESULTS: We searched several databases up to 31 May 2021, for studies that reported the prevalence of SI. The primary endpoint was overall prevalence and prevalence according to a range of diagnostic criteria [National Lipid Association (NLA), International Lipid Expert Panel (ILEP), and European Atherosclerosis Society (EAS)] and in different disease settings. The secondary endpoint was to identify possible risk factors for SI. A random-effects model was applied to estimate the overall pooled prevalence. A total of 176 studies [112 randomized controlled trials (RCTs); 64 cohort studies] with 4 143 517 patients were ultimately included in the analysis. The overall prevalence of SI was 9.1% (95% confidence interval 8.0-10%). The prevalence was similar when defined using NLA, ILEP, and EAS criteria [7.0% (6.0-8.0%), 6.7% (5.0-8.0%), 5.9% (4.0-7.0%), respectively]. The prevalence of SI in RCTs was significantly lower compared with cohort studies [4.9% (4.0-6.0%) vs. 17% (14-19%)]. The prevalence of SI in studies including both primary and secondary prevention patients was much higher than when primary or secondary prevention patients were analysed separately [18% (14-21%), 8.2% (6.0-10%), 9.1% (6.0-11%), respectively]. Statin lipid solubility did not affect the prevalence of SI [4.0% (2.0-5.0%) vs. 5.0% (4.0-6.0%)]. Age [odds ratio (OR) 1.33, P = 0.04], female gender (OR 1.47, P = 0.007), Asian and Black race (P < 0.05 for both), obesity (OR 1.30, P = 0.02), diabetes mellitus (OR 1.26, P = 0.02), hypothyroidism (OR 1.37, P = 0.01), chronic liver, and renal failure (P < 0.05 for both) were significantly associated with SI in the meta-regression model. Antiarrhythmic agents, calcium channel blockers, alcohol use, and increased statin dose were also associated with a higher risk of SI. CONCLUSION: Based on the present analysis of >4 million patients, the prevalence of SI is low when diagnosed according to international definitions. These results support the concept that the prevalence of complete SI might often be overestimated and highlight the need for the careful assessment of patients with potential symptoms related to SI.
引用
- Bytyçi I, Penson PE, Mikhailidis DP, et al. Prevalence of statin intolerance: a meta-analysis. Eur Heart J. 2022. PMID: 35169843. doi:10.1093/eurheartj/ehac015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。